- POINT Biopharma Global Inc (NASDAQ:PNT) priced its public offering of 13.9 million shares at $9.00 per share, with gross proceeds of $125 million.
- The offer price represents a discount of almost 12% from the last close price of $10.18 on Tuesday.
- Underwriters have an option to purchase up to an additional 2.01 million shares.
- POINT will use the proceeds to fund clinical and preclinical research and development programs.
- Related: POINT Biopharma Shares Jump After Updated Efficacy, Safety Data From Prostate Cancer Candidate.
- Akero Therapeutics Inc (NASDAQ:AKRO) commenced an underwritten public offering of $175.0 million.
- Underwriters have an option to purchase up to an additional $26.25 million of shares.
- Related: Akero Therapeutics Shares More Than Double After Lead NASH Candidate Aces Mid-Stage Study
- Price Action: AKRO shares are down 6.51% at $27.16, and PNT shares are down 11.40% at $9.02 on the last check Wednesday.
Riot Announces November 2022 Production And Operations Updates; Produced 521 Bitcoins, An Increase Of ~12% As Compared To November 2021; Riot Held ~6,897 BTC As Of November 30, 2022; Riot Sold 450 BTC, Generating Net Proceeds Of ~$8.1M
Riot Blockchain, Inc. (NASDAQ:RIOT) ("Riot" or "the Company"), an industry leader in Bitcoin ("BTC") mining and data center hosting, announces unaudited production and operations updates for
